Evidence map›Paper›PMID 31063094›Full record

ArticleEpidemiology and infection2019

Kinetics of serum antibodies in response to infection with Yersinia enterocolitica.

I Vaitkeviciute, P F M Teunis, W van Pelt, K A Krogfelt

Open access · hybridAbstract read
In one paragraph

Article in Epidemiology and infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

I VaitkeviciuteDepartment of Bacteria,Parasites and Fungi,Statens Serum Institut,Copenhagen,Denmark.
P F M TeunisHubert Department of Global Health,Rollins School of Public Health,Emory University,Atlanta GA,USA.ORCID 0000-0003-1904-6044
W van PeltCentre for Infectious Disease Control,RIVM,Bilthoven,The Netherlands.
K A KrogfeltDepartment of Bacteria,Parasites and Fungi,Statens Serum Institut,Copenhagen,Denmark.
Statens Serum Institut · DKEmory University · USNational Institute for Public Health and the Environment · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Information on the kinetics of the serum antibody response to infection with Yersinia enterocolitica is essential to allow the estimation and comparison of seroconversion rates in a diversity of pools of cross-sectional serum antibody measurements. Data from 94 patients with acute enteritis caused by Yersinia infection were used. The follow-up period for the longitudinal study was 36 months, addressed by questionnaire. An indirect enzyme-linked immunosorbent assay method was adapted to determine the concentration of antibodies against Y. enterocolitica in human sera. A mathematical within-host model was used to describe the interaction between pathogen and immune system and the waning of immunity after clearing of the pathogen. All observed antibodies (IgG, IgM, IgA) reached peak levels shortly after infection and then decayed slowly indicating that the median levels decreased only little during the observation period. Estimated maximum peak antibody levels were highest in IgG. Seroresponse curves of all antibodies showed large individual variation between patients. There was no apparent pattern of variation with age, nor any notable difference between genders. Estimated half-times were very long for all antibodies, and their posterior distributions were highly skewed. IgA appeared to have the most persistent antibody response, compared with IgG and IgM. Median peak levels of all three antibodies were similar. There was no significance found between peak antibody levels and severity of symptoms of gastrointestinal infection and severity of joint pain. Our findings allow the use of cross-sectional serum antibody measurements as biomarkers, to estimate seroconversion rates. Such seroincidence estimates include asymptomatic seroconversions, thereby avoiding under-reporting, and allows the comparison of infection pressures among countries, independent of their healthcare and surveillance systems.

Indexed as

Antibody FormationAdultAntibodies, BacterialDenmarkEnteritisEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MLongitudinal StudiesMaleMiddle AgedModels, TheoreticalSerumAntibodies, BacterialImmunoglobulin AImmunoglobulin GImmunoglobulin MGastrointestinal infectionseroconversion ratesserologyYersinia enterocolitica

Identifiers

PMID31063094
PMCPMC6518524
OpenAlexW2927078502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.